{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:40:27Z","timestamp":1790224827434,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Many locally advanced and metastatic salivary gland carcinomas (SGC) lack therapeutic targets.\n                    <jats:italic>Enfortumab vedotin<\/jats:italic>\n                    , an antibody\u2013drug conjugate binding to Nectin-4, recently gained FDA approval for third-line urothelial carcinoma. Therefore, the aim of this study was to assess the expression of Nectin-4 in primary SGC and corresponding lymph node metastases and to correlate it with clinicopathological data. Immunohistochemical staining for Nectin-4 was performed for patients who had undergone surgery with curative intent for primary SGC of the parotid or submandibular gland in a tertiary referral center between 1990 and 2019. One hundred twenty-two primary SGC and twenty corresponding lymph node metastases were included. Nectin-4 was expressed in 80.3% of primary SGC with a mean Histo(H-)score of 61.2 and in 90.0% of lymph node metastases with a mean H-score of 75.6. A moderate or high Nectin-4 expression was found in 25.9% of salivary duct carcinomas (SaDu) and in 30.7% of adenoid cystic carcinomas (ACC). SaDu patients with a lower T-stage (p\u2009=\u20090.04), no loco-regional lymph node metastases (p\u2009=\u20090.049), no vascular invasion (p\u2009=\u20090.04), and no perineural spread (p\u2009=\u20090.03) showed a significantly higher mean Nectin-4 H-score. There was a statistical tendency towards a more favorable disease-free survival among SaDu patients with a higher Nectin-4 expression (p\u2009=\u20090.09). Nectin-4 is expressed in SGC and therefore represents a potential therapeutic target, especially in entities with a high rate of local recurrence and metastatic spread such as SaDu and ACC.\n                  <\/jats:p>","DOI":"10.1007\/s10585-023-10222-w","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T05:01:38Z","timestamp":1690002098000},"page":"395-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker"],"prefix":"10.1007","volume":"40","author":[{"given":"Marcel","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nachtsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Shabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Suchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Peter","family":"Klu\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Wolber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"5","key":"10222_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ijc.20740","volume":"114","author":"AL Carvalho","year":"2005","unstructured":"Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114(5):806\u2013816","journal-title":"Int J Cancer"},{"issue":"10","key":"10222_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/0360-3016(86)90314-7","volume":"12","author":"PJ Fitzpatrick","year":"1986","unstructured":"Fitzpatrick PJ, Theriault C (1986) Malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 12(10):1743\u20131747","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10222_CR3","unstructured":"WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 9"},{"key":"10222_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.oraloncology.2018.04.022","volume":"82","author":"E Boon","year":"2018","unstructured":"Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA et al (2018) Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. Oral Oncol 82:29\u201333","journal-title":"Oral Oncol"},{"issue":"Suppl 1","key":"10222_CR5","first-page":"E820","volume":"38","author":"ML Johnston","year":"2016","unstructured":"Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ et al (2016) Salivary duct carcinoma: treatment, outcomes, and patterns of failure. Head Neck 38(Suppl 1):E820\u2013E826","journal-title":"Head Neck"},{"key":"10222_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","volume":"66","author":"S Alfieri","year":"2017","unstructured":"Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF et al (2017) Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol 66:58\u201363","journal-title":"Oral Oncol"},{"key":"10222_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41199-016-0011-z","volume":"1","author":"AV Chintakuntlawar","year":"2016","unstructured":"Chintakuntlawar AV, Okuno SH, Price KA (2016) Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers Head Neck 1:11","journal-title":"Cancers Head Neck"},{"issue":"4","key":"10222_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s12105-018-0984-5","volume":"13","author":"L Liang","year":"2019","unstructured":"Liang L, Williams MD, Bell D (2019) Expression of PTEN, androgen receptor, HER2\/neu, cytokeratin 5\/6, estrogen receptor-Beta, HMGA2, and PLAG1 in salivary duct carcinoma. Head Neck Pathol 13(4):529\u2013534","journal-title":"Head Neck Pathol"},{"key":"10222_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.693394","volume":"11","author":"K Egebjerg","year":"2021","unstructured":"Egebjerg K, Harwood CD, Woller NC, Kristensen CA, Mau-Sorensen M (2021) HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis. Front Oncol 11:693394","journal-title":"Front Oncol"},{"key":"10222_CR10","doi-asserted-by":"publisher","first-page":"S663","DOI":"10.1016\/j.annonc.2020.08.1034","volume":"31","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto R, Wirth L, Muzaffar J, Rodriguez C, Xia B, Perez C et al (2020) 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). Ann Oncol 31:S663","journal-title":"Ann Oncol"},{"issue":"4","key":"10222_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12105-021-01325-5","volume":"15","author":"P Wolber","year":"2021","unstructured":"Wolber P, Nachtsheim L, Hoffmann F, Klussmann JP, Meyer M, von Eggeling F et al (2021) Trophoblast cell surface antigen 2 (Trop-2) protein is highly expressed in salivary gland carcinomas and represents a potential therapeutic target. Head Neck Pathol 15(4):1147\u20131155","journal-title":"Head Neck Pathol"},{"issue":"16","key":"10222_CR12","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.3390\/ijms23169037","volume":"23","author":"M Mayer","year":"2022","unstructured":"Mayer M, Nachtsheim L, Hoffmann F, von Eggeling F, Guntinas-Lichius O, Prinz J et al (2022) CD138 is expressed in different entities of salivary gland cancer and their lymph node metastases and therefore represents a potential therapeutic target. Int J Mol Sci 23(16):9037","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10222_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdx771","volume":"29","author":"C Fushimi","year":"2018","unstructured":"Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29(4):979\u2013984","journal-title":"Ann Oncol"},{"issue":"2","key":"10222_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37(2):125\u2013134","journal-title":"J Clin Oncol"},{"issue":"8","key":"10222_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrm2457","volume":"9","author":"Y Takai","year":"2008","unstructured":"Takai Y, Miyoshi J, Ikeda W, Ogita H (2008) Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9(8):603\u2013615","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"10222_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1515\/BC.2004.116","volume":"385","author":"H Nakanishi","year":"2004","unstructured":"Nakanishi H, Takai Y (2004) Roles of nectins in cell adhesion, migration and polarization. Biol Chem 385(10):885\u2013892","journal-title":"Biol Chem"},{"issue":"46","key":"10222_CR17","doi-asserted-by":"publisher","first-page":"43205","DOI":"10.1074\/jbc.M103810200","volume":"276","author":"N Reymond","year":"2001","unstructured":"Reymond N, Fabre S, Lecocq E, Adela\u0131de J, Dubreuil P, Lopez M (2001) Nectin4\/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1\/PRR1 through V domain interaction. J Biol Chem 276(46):43205\u201343215","journal-title":"J Biol Chem"},{"issue":"30","key":"10222_CR18","doi-asserted-by":"publisher","first-page":"27006","DOI":"10.1074\/jbc.M203228200","volume":"277","author":"S Fabre","year":"2002","unstructured":"Fabre S, Reymond N, Cocchi F, Menotti L, Dubreuil P, Campadelli-Fiume G et al (2002) Prominent role of the Ig-like V domain in trans-interactions of nectins Nectin3 and nectin 4 bind to the predicted C\u2013C\u2032\u2013C\u2033\u2013D beta-strands of the nectin1 V domain. J Biol Chem 277(30):27006\u201313","journal-title":"J Biol Chem"},{"issue":"5","key":"10222_CR19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","volume":"134","author":"MS DeRycke","year":"2010","unstructured":"DeRycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M et al (2010) Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 134(5):835\u2013845","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"10222_CR20","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1158\/0008-5472.CAN-09-0016","volume":"69","author":"A Takano","year":"2009","unstructured":"Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K et al (2009) Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Can Res 69(16):6694\u20136703","journal-title":"Can Res"},{"key":"10222_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5273","author":"Y Liu","year":"2021","unstructured":"Liu Y, Han X, Li L, Zhang Y, Huang X, Li G et al (2021) Role of Nectin-4 protein in cancer (review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2021.5273","journal-title":"Int J Oncol"},{"key":"10222_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.biocel.2018.07.011","volume":"102","author":"S Siddharth","year":"2018","unstructured":"Siddharth S, Nayak A, Das S, Nayak D, Panda J, Wyatt MD et al (2018) The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-beta4. Int J Biochem Cell Biol 102:151\u2013160","journal-title":"Int J Biochem Cell Biol"},{"issue":"14","key":"10222_CR23","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/onc.2015.240","volume":"35","author":"E Bousquet","year":"2016","unstructured":"Bousquet E, Calvayrac O, Mazieres J, Lajoie-Mazenc I, Boubekeur N, Favre G et al (2016) RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene 35(14):1760\u20131769","journal-title":"Oncogene"},{"issue":"1","key":"10222_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","volume":"375","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z et al (2016) A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett 375(1):179\u2013189","journal-title":"Cancer Lett"},{"issue":"4","key":"10222_CR25","first-page":"412","volume":"11","author":"KS Hanna","year":"2020","unstructured":"Hanna KS (2020) Advancements in therapy for bladder cancer: enfortumab vedotin. J Adv Pract Oncol 11(4):412\u2013417","journal-title":"J Adv Pract Oncol"},{"issue":"10","key":"10222_CR26","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y et al (2016) Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76(10):3003\u20133013","journal-title":"Cancer Res"},{"key":"10222_CR27","unstructured":"FDA. FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer. 2019"},{"key":"10222_CR28","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons"},{"key":"10222_CR29","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12105-022-01448-3","volume":"16","author":"P Wolber","year":"2022","unstructured":"Wolber P, Mayer M, Nachtsheim L, Prinz J, Klussmann JP, Quaas A et al (2022) Expression of mucins in different entities of salivary gland cancer: highest expression of mucin-1 in salivary duct carcinoma\u202f: mucin-1\u2014highest expression in salivary duct carcinoma. Head Neck Pathol 16:792","journal-title":"Head Neck Pathol"},{"issue":"11","key":"10222_CR30","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/ng.3096","volume":"46","author":"I Weinreb","year":"2014","unstructured":"Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B et al (2014) Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 46(11):1166\u20131169","journal-title":"Nat Genet"},{"key":"10222_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.18632\/oncotarget.28299","volume":"13","author":"C Sanders","year":"2022","unstructured":"Sanders C, Lau JF, Dietrich D, Strieth S, Brossart P, Kristiansen G (2022) Nectin-4 is widely expressed in head and neck squamous cell carcinoma. Oncotarget 13:1166\u20131173","journal-title":"Oncotarget"},{"issue":"18","key":"10222_CR32","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.3390\/cancers14184411","volume":"14","author":"S Rodler","year":"2022","unstructured":"Rodler S, Eismann L, Schlenker B, Casuscelli J, Brinkmann I, Sendelhofert A et al (2022) Expression of Nectin-4 in variant histologies of bladder cancer and its prognostic value-need for biomarker testing in high-risk patients? Cancers (Basel). 14(18):4411","journal-title":"Cancers (Basel)."},{"issue":"8","key":"10222_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM et al (2021) Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol 29(8):619\u2013625","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"20","key":"10222_CR34","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798\u20133807","journal-title":"J Clin Oncol"},{"key":"10222_CR35","unstructured":"FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer 2021. [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-enfortumab-vedotin-ejfv-locally-advanced-or-metastatic-urothelial-cancer#:~:text=FDA%20granted%20accelerated%20approval%20in,locally%20advanced%20or%20metastatic%20setting"},{"issue":"12","key":"10222_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135","journal-title":"N Engl J Med"},{"key":"10222_CR37","unstructured":"Padcev (enfortumab vedotin). An overview of Padcev and why it is authorised in the EU 2022 . Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/padcev-epar-medicine-overview_en.pdf"},{"issue":"21","key":"10222_CR38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21037\/atm-20-1849","volume":"8","author":"J Ran","year":"2020","unstructured":"Ran J, Zou H, Li X, Guo F, Xu W, Han W (2020) A population-based competing risk survival analysis of patients with salivary duct carcinoma. Ann Transl Med 8(21):1355","journal-title":"Ann Transl Med"},{"key":"10222_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04278-6","author":"L Nachtsheim","year":"2022","unstructured":"Nachtsheim L, Mayer M, Meyer MF, Oesterling F, Kajueter H, Arolt C et al (2022) Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany. J Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-022-04278-6","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10222_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100602","volume":"7","author":"C van Herpen","year":"2022","unstructured":"van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A et al (2022) Salivary gland cancer: ESMO-European reference network on rare adult solid cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open 7(6):100602","journal-title":"ESMO Open"},{"issue":"6","key":"10222_CR41","first-page":"3045","volume":"37","author":"S Jang","year":"2017","unstructured":"Jang S, Patel PN, Kimple RJ, McCulloch TM (2017) Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck. Anticancer Res 37(6):3045\u20133052","journal-title":"Anticancer Res"},{"issue":"4","key":"10222_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10120-018-00923-7","volume":"22","author":"MA Shah","year":"2019","unstructured":"Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E et al (2019) Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric\/gastroesophageal junction cancer. Gastric Cancer 22(4):803\u2013816","journal-title":"Gastric Cancer"},{"key":"10222_CR43","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fmed.2019.00200","volume":"6","author":"J Zeindler","year":"2019","unstructured":"Zeindler J, Soysal SD, Piscuoglio S, Ng CKY, Mechera R, Isaak A et al (2019) Nectin-4 expression is an independent prognostic biomarker and associated with better survival in triple-negative breast cancer. Front Med (Lausanne) 6:200","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10222_CR44","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s12105-017-0882-2","volume":"12","author":"JB Jalaly","year":"2018","unstructured":"Jalaly JB, Sanati S, Chernock RD, Dibe DG, El-Mofty SK (2018) Salivary duct carcinoma and invasive ductal carcinoma of the breast: a comparative immunohistochemical study. Head Neck Pathol 12(4):488\u2013492","journal-title":"Head Neck Pathol"},{"issue":"4","key":"10222_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biomedicines9040355","volume":"9","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Murata M, Oda Y, Furue M, Ito T (2021) Nectin cell adhesion molecule 4 (NECTIN4) expression in cutaneous squamous cell carcinoma: a new therapeutic target? Biomedicines 9(4):355","journal-title":"Biomedicines"},{"key":"10222_CR46","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2021-0052","author":"P Giridhar","year":"2022","unstructured":"Giridhar P, Venkatesulu BP, Yoo R et al (2022) Demography, patterns of care, and survival outcomes in patients with salivary duct carcinoma: an individual patient data analysis of 857 patients. Future Sci OA. https:\/\/doi.org\/10.2144\/fsoa-2021-0052","journal-title":"Future Sci OA"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-023-10222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-023-10222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T07:08:08Z","timestamp":1694416088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-023-10222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10222"],"URL":"https:\/\/doi.org\/10.1007\/s10585-023-10222-w","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"7 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institution or practice at which the studies were conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors approved the final submitted manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in this study (no identifying information about participants is available in this article).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}